Comparative Pharmacology
Head-to-head clinical analysis: TESTOSTERONE UNDECANOATE versus TESTRED.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TESTOSTERONE UNDECANOATE versus TESTRED.
TESTOSTERONE UNDECANOATE vs TESTRED
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Testosterone undecanoate is a prodrug of testosterone, which binds to androgen receptors (ARs) in target tissues, leading to activation of androgen-responsive genes that promote male sexual development, maintenance of secondary sexual characteristics, and anabolic effects. It also exerts negative feedback on the hypothalamic-pituitary-gonadal axis, suppressing gonadotropin secretion.
Testosterone is an androgen receptor agonist, promoting development of male secondary sexual characteristics and anabolic effects.
1000 mg intramuscularly every 10-14 weeks, followed by a second dose at 6 weeks; maintenance 1000 mg every 10-14 weeks.
Testosterone enanthate 200 mg intramuscularly every 2 weeks.
None Documented
None Documented
Terminal elimination half-life: 20.7 days (range 16.5–25.7 days) after intramuscular injection. This prolonged half-life is due to slow release from the oily depot in muscle. With oral administration, half-life is approximately 7–13 hours.
Terminal elimination half-life for testosterone is 2-4 hours; testosterone enanthate has a half-life of 4-5 days due to slow release from the oily depot. Clinical context: shorter half-life requires more frequent dosing for stable serum levels.
Renal (5-10% as glucuronide and sulfate conjugates, <1% as unchanged testosterone), Fecal (90% as metabolites via bile). No significant biliary excretion of active drug.
Approximately 90% of administered testosterone is excreted in urine as glucuronide and sulfate conjugates of testosterone and its metabolites (androsterone, etiocholanolone). About 6% is excreted in feces via bile. Unchanged testosterone excretion is negligible (<1%).
Category D/X
Category C
Androgen
Androgen